Business Context and Reporting Period
This Form 8-K filing by Lunai Bioworks Inc. (LNAI) covers the reporting period of June 11, 2026. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance.
Material Changes
On June 11, 2026, the Company received confirmation from The Nasdaq Stock Market LLC that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the "Bid Price Rule," which requires a minimum bid price of $1.00 per share. This compliance was achieved by meeting the terms set forth in previous Nasdaq Hearings Panel decisions and extension letters dated April 20, 2026, and May 12, 2026.
Outlook, Risks, and Contingencies
Mandatory Monitoring: Pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company is subject to a mandatory Panel monitor for one year from the date of the compliance letter.
Consequences of Future Non-Compliance: During the monitoring period, if the Company falls out of compliance with the Bid Price Rule again:
- The Company will not be permitted to submit a plan of compliance.
- Nasdaq staff will not grant additional time to regain compliance.
- No cure or compliance period will be afforded.
- Nasdaq staff will issue a delist determination letter.
Investor Verification Checklist
- Verify the current trading price of LNAI to ensure it remains above the $1.00 minimum bid price threshold.
- Monitor the Company's stock price daily over the next 12 months to avoid immediate delisting risks associated with the mandatory monitoring period.
- Review the specific terms of the April 20, 2026, and May 12, 2026, extension letters to understand the exact conditions met for compliance.
- Check for any subsequent filings regarding the Company's financial health, as this 8-K does not disclose liquidity or operational metrics.